Drug Trial Radar · NCT03738475
Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
Last checked: Nov 19, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Nov 11, 2018
Primary completion
Jun 24, 2019
Study completion Jul 22, 2019
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- COUR Pharmaceutical Development Company, Inc.
- First posted
- Nov 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects enrolled in this study will be evaluated for immune responses and histological changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten challenge.
Conditions
- Celiac Disease
Interventions
TIMP-GLIADrug
8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
PlaceboDrug
Administered intravenously on days 1 and 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Interferon-Gamma Spot Forming Units (IFN-gamma SFUs) in a Gliadin-specific Enzyme-linked Immunospot (ELISpot) at Day 20Time frame: Baseline (Day 15/Day 1), Day 20
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Jacksonville Center for Clinical Research
Jacksonville, Florida
Advanced Clinical Research
Meridian, Idaho
Indianapolis Gastroenterology Research Foundation
Indianapolis, Indiana
Beth Isreal Deaconess Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Prism Clinical Research
Saint Paul, Minnesota
Rapid Medical Research
Beachwood, Ohio
Advanced Clinical Research
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.